| Rat Target Sites | Mouse Target Sites | TD50 (mg/kg/day) | |||
| Male | Female | Male | Female | Rat | Mouse |
| kid liv | liv vsc | tba | no test | 0.799m,P | 0.679 |
| Hamster Target Sites | TD50 (mg/kg/day) |
|
| Male | Female | |
| liv | liv | 14.2m |
Key to the Table Above
The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.
For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.
Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.
TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.
A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.
Chemical (Synonym) CAS # Species Sex Strain Route Xpo+Xpt PaperNum 0 Dose 1 Dose 2 Dose 3 Dose Literature Reference or NCI/NTP:Site Path Site Path Notes TD50 DR Pval AuOp LoConf UpConf Cntrl 1 Inc 2 Inc 3 Inc Brkly Code
N-NITROSOPYRROLIDINE 930-55-2 4635 H f syg wat 24m24 1503 0 .573mg 2.18mg 4.50mg Ketkar;zkko,104,75-79;1982 liv hct 35.9mg * P<.008 + 12.4mg 770.mg 0/50 0/30 1/30 3/30 tba mix 8.44mg * P<.002 4.27mg 39.7mg 3/50 2/30 10/30 8/30 4636 H m syg wat 24m24 1503 0 .504mg 1.92mg 3.96mg liv hct 8.88mg * P<.0005 + 4.67mg 20.4mg 0/50 1/30 2/30 10/30 liv hae 130.mg * P<.2 21.2mg n.s.s. 0/50 0/30 0/30 1/30 tba mix 9.26mg * P<.007 4.14mg 159.mg 8/50 3/30 4/30 13/30 4637 M m swi gav 76w76 1713 0 1.19mg Shah;zkko,109,203-207;1985 tba mix e .679mg P<.002 + .309mg 2.84mg 1/20 10/20 4638 R m chm wat 84w84 1774 0 3.00mg Chung;canr,46,1285-1289;1986 liv hpc .659mg P<.0005 + .340mg 1.35mg 0/23 20/23 liv nnd 1.13mg P<.0005 + .601mg 2.40mg 0/23 16/23 liv clc 14.8mg P<.1 + 3.63mg n.s.s. 0/23 2/23 4639 R b clw wat 30m30 1958 0 34.0ug 69.0ug .137mg .275mg .550mg 1.10mg 1.65mg 2.20mg 2.75mg 3.30mg 4.40mg 5.50mg 6.60mg 8.80mg 17.6mg Gray;canr,51,6470-6491;1991 liv hct e 1.70mg * P<.0005 + 1.24mg 2.36mg 8/246 0/12 0/12 1/12 5/12 6/12 9/12 12/12 12/12 11/12 10/12 12/12 9/12 10/12 11/12 12/12 liv hpc e 2.20mg * P<.0005 + 1.63mg 3.03mg 2/246 0/12 0/12 1/12 5/12 4/12 7/12 10/12 11/12 10/12 9/12 11/12 9/12 9/12 11/12 12/12 bil ben e 99.7mg * P<.003 + 40.1mg 814.mg 2/246 0/12 0/12 0/12 1/12 0/12 1/12 0/12 0/12 0/12 1/12 0/12 2/12 2/12 2/12 0/12 nsp tum e 350.mg * P<.04 86.1mg n.s.s. 0/246 0/12 0/12 0/12 0/12 0/12 0/12 0/12 0/12 1/12 0/12 0/12 0/12 0/12 1/12 0/12 4640 R f f34 wat 7m26 1795 0 1.00mg Michejda;canr,46,2252-2256;1986/pers.comm. liv hpc e noTD50 P<.0005 + n.s.s. .409mg 0/20 20/20 liv nnd e 2.51mg P<.04 + .915mg n.s.s. 1/20 6/20 liv hes e 15.0mg P<.3 + 2.44mg n.s.s. 0/20 1/20 liv clc e 15.0mg P<.3 + 2.44mg n.s.s. 0/20 1/20 tba mix e noTD50 P<.6 + n.s.s. n.s.s. 19/20 20/20 4641 R f f34 wat 12m26 2022 0 1.65mg Lijinsky;clet,12,99-103;1981 liv hpc e .439mg P<.0005 + .179mg 1.04mg 1/20 19/20 liv mix e .439mg P<.0005 + .179mg 1.04mg 1/20 19/20 liv clc e 4.49mg P<.007 + 1.70mg 51.8mg 0/20 5/20 liv cho e 7.95mg P<.04 2.40mg n.s.s. 0/20 3/20 liv lyp e 7.95mg P<.04 2.40mg n.s.s. 0/20 3/20 liv sar e 25.2mg P<.3 4.10mg n.s.s. 0/20 1/20 tba tum e no dre P=1. .326mg n.s.s. 20/20 19/20 4642 R f mrw wat 16m24 228 0 5.21mg Greenblatt;jnci,48,1687-1696;1972/1973 liv hpc e 1.81mg P<.0005 + .802mg 4.45mg 0/20 13/15 tba mix e 4.49mg P<.3 1.06mg n.s.s. 14/20 13/15 4643 R m mrw wat 16m24 228 0 3.65mg liv hpc e 1.58mg P<.0005 + .731mg 3.93mg 0/20 12/15 tes pms e 8.21mg P<.007 2.82mg 123.mg 0/20 4/15 tba mix e 2.03mg P<.004 .807mg 16.5mg 6/20 12/15 4644 R b sda wat 23m30 371 0 .300mg 1.00mg 3.00mg 10.0mg Preussmann;zkko,90,161-166;1977 liv hpc as 3.26mg Z P<.0005 2.23mg 5.01mg 0/61 0/60 13/62 30/38 (9/24) liv hpa as 55.5mg * P<.005 20.9mg 857.mg 0/61 3/60 4/62 1/38 5/24 tba mal as 2.37mg Z P<.0005 + 1.60mg 3.90mg 6/61 12/60 20/62 32/38 (11/24) tba ben as 71.1mg * P<.2 20.9mg n.s.s. 5/61 7/60 9/62 3/38 6/24 4645 R m sda wat 20m30 1717m 0 .657mg Hoos;clet,26,77-82;1985 liv hpc .648mg P<.0005 + .454mg .958mg 0/80 53/80 tba mal .631mg P<.0005 .412mg 1.10mg 19/80 60/80 4646 R m sda wat 10m30 1717n 0 .657mg liv hpc .489mg P<.0005 + .346mg .712mg 0/80 61/80 tba mal .501mg P<.0005 .333mg .826mg 19/80 65/80 4647 R m sda wat 37m38 1838 0 28.6ug 95.0ug .286mg Berger;carc,8,1635-1643;1987/pers.comm. liv mix a 2.43mg * P<.0005 + 1.44mg 4.68mg 3/500 1/80 4/80 17/80 liv hpc a 4.06mg * P<.0005 + 2.14mg 9.15mg 0/500 1/80 0/80 12/80 liv hpa a 8.13mg * P<.0005 + 3.42mg 31.2mg 1/500 0/80 2/80 5/80 unt tum a 7.03mg Z P<.1 + 1.78mg n.s.s. 1/500 2/80 1/80 (0/80) git mix a 14.9mg * P<.4 + 3.25mg n.s.s. 26/500 6/80 7/80 6/80 liv hmm a 55.7mg * P<.3 9.07mg n.s.s. 0/500 0/80 1/80 0/80 tba mal a 2.03mg * P<.007 + .933mg 38.1mg 144/500 23/80 28/80 35/80 tba ben a no dre P=1. 1.18mg n.s.s. 362/500 63/80 59/80 55/80
See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.
A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.
For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.
The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.
A Supplementary Dataset gives details on dosing and survival for each experiment.
Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.
PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.